文献速递膀胱癌与上尿路尿路上皮癌

膀胱内灌注抗PD-1免疫检查点抑制剂治疗小鼠尿路上皮膀胱癌

Intravesical Anti-PD-1 Immune Checkpoint Inhibition Treats Urothelial Bladder Cancer in a Mouse Model.
PubMed 文献 · J Urol · 2020-12-24

该研究在MBT2细胞原位小鼠膀胱癌模型中比较膀胱内灌注抗PD-1、腹腔注射抗PD-1与膀胱内化疗的疗效。结果显示膀胱内抗PD-1可有效治疗局部膀胱癌,总生存与全身给药相似,且增加肿瘤内CD8+细胞浸润并诱导长期免疫,避免化疗毒性。

要点

  • 膀胱内灌注抗PD-1与原位膀胱癌小鼠模型中全身给药总生存相似
  • 膀胱内抗PD-1增加肿瘤CD8+细胞浸润并诱导长期免疫记忆
  • 抗体治疗避免了膀胱内化疗观察到的毒性

核心结论

  • 膀胱内灌注抗PD-1是治疗局部膀胱癌的有前景途径,在该小鼠模型中总生存与全身抗PD-1相当。

研究设计与样本

  • 研究采用MBT2细胞灌注同系野生型C3H小鼠的原位尿路上皮膀胱癌模型,每组10只小鼠接受膀胱内抗PD-1、腹腔抗PD-1或膀胱内化疗。

主要发现

  • 膀胱内灌注抗PD-1成功治疗局部膀胱癌,总生存与全身途径抗PD-1相似。
  • 两种途径抗PD-1均较对照抗体提供显著生存优势。
  • 抗PD-1增加肿瘤内CD8+细胞浸润,膀胱内给药尤为明显。
  • 抗体治疗避免了膀胱内化疗观察到的毒性。
  • 初始抗PD-1治疗清除肿瘤的小鼠在3-9个月后再次接种肿瘤未生长,提示存在长期免疫;初始丝裂霉素治疗小鼠则肿瘤生长,提示化疗未产生免疫。

临床怎么用

  • 该小鼠模型结果提示膀胱内抗PD-1可能作为局部膀胱癌的治疗选择,但需临床研究验证。

局限性

  • 研究为小鼠原位模型,样本量每组10只,结果外推至人类需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Nonmuscle-invasive bladder cancer is treated by resection within the bladder and bladder instillment with bacillus Calmette-Guérin or chemotherapy. For bacillus Calmette-Guérin-refractory disease, systemic anti-PD-1 (programmed cell death protein 1) immune checkpoint inhibition is a treatment. Our aim is to test whether intravesical instillment with anti-PD-1 inhibitor treats localized bladder cancer as effectively as systemic administration. MATERIALS AND METHODS: We investigated an orthotopic mouse model of urothelial bladder cancer using MBT2 cells instilled into the bladders of syngeneic, wild-type C3H mice. Groups of 10 mice received each treatment for comparison of intravesical anti-PD-1, intraperitoneal anti-PD1, and intravesical chemotherapy. The primary outcome was overall survival and secondary outcomes included long-term immunity and toxicity. RESULTS: Anti-PD-1 administered by bladder instillment (intravesical route) successfully treats localized bladder cancer and has similar overall survival to anti-PD-1 by systemic route. Anti-PD-1 by either route provides a significant survival advantage over control antibody. Anti-PD-1 increases CD8+ cell infiltration in tumors, particularly when administered intravesically. Antibody treatment avoids toxicity observed for intravesical chemotherapy. Mice who cleared their tumors after initial treatment were rechallenged with tumor engraftment 3-9 months later without any additional treatment. Initial anti-PD-1-treated mice did not grow tumors when rechallenged, which suggests long-term immunity exists, but initial mitomycin-treated mice readily grew tumors indicating no immunity occurred by chemotherapy treatment. CONCLUSIONS: Intravesical administration of anti-PD-1 is a promising treatment route for localized bladder cancer, with comparable overall survival to systemic anti-PD-1 in this mouse model. Intravesical anti-PD-1 increases CD8+ T cells in treated tumors and long-term immunity was seen to tumor rechallenge.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Kirschner AN, Wang J, Rajkumar-Calkins A, et al. Intravesical Anti-PD-1 Immune Checkpoint Inhibition Treats Urothelial Bladder Cancer in a Mouse Model. J Urol. 2020. PMID: 33356477. doi:10.1097/JU.0000000000001576

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。